Suzuki Yuta, Kaneko Hidehiro, Yano Yuichiro, Okada Akira, Fujiu Katsuhito, Matsuoka Satoshi, Michihata Nobuaki, Jo Taisuke, Takeda Norifumi, Morita Hiroyuki, Node Koichi, Yasunaga Hideo, Oparil Suzanne, Komuro Issei
Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan.
Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
Hypertens Res. 2023 Apr;46(4):856-867. doi: 10.1038/s41440-022-01146-1. Epub 2023 Jan 19.
Little is known about the relationship between blood pressure (BP) and incident cardiovascular disease (CVD) in people with proteinuria and a preserved estimated glomerular filtration rate (eGFR). This study sought to investigate the association of BP with CVD risk in adults with proteinuria and preserved eGFR. We studied 188,837 individuals with proteinuria and preserved eGFR ≥60 mL/min/1.73 m. We categorized individuals who were not taking BP-lowering medications into four groups based on the 2017 American College of Cardiology/American Heart Association BP guideline and categorized those who were taking BP-lowering medications using the same BP ranges. The primary outcome was a composite CVD endpoint that included myocardial infarction, angina pectoris, stroke, and heart failure. Over a mean follow-up of 1,050 days, 7,039 CVD events were identified. Compared with normal BP, stage 1 hypertension (hazard ratio [HR]: 1.30, 95% confidence interval [95% CI]: 1.21-1.40) and stage 2 hypertension (HR: 2.17, 95% CI: 2.01-2.34) were associated with an increased risk for CVD events among medication-naïve individuals. Only stage 2 hypertension range (HR: 1.19, 95% CI: 1.02-1.38) was associated with an increased CVD event risk among people taking BP-lowering medications. Restricted cubic spline analysis showed that the risk of CVD events increased monotonically with BP at an SBP/DBP > 120/80 mmHg among medication-naïve individuals, but risk increased only at an SBP/DBP > 140/90 mmHg among individuals taking BP-lowering medications. In conclusion, among people with proteinuria and preserved eGFR, stage 1 and stage 2 hypertension were associated with a greater risk of CVD among medication-naïve individuals, whereas only stage 2 hypertension was associated with an increased CVD risk among those taking BP-lowering medications.
关于蛋白尿且估算肾小球滤过率(eGFR)保留的人群中血压(BP)与心血管疾病(CVD)发病之间的关系,目前所知甚少。本研究旨在调查蛋白尿且eGFR保留的成年人中血压与CVD风险的关联。我们研究了188,837例蛋白尿且eGFR保留≥60 mL/min/1.73 m²的个体。我们根据2017年美国心脏病学会/美国心脏协会血压指南,将未服用降压药物的个体分为四组,并使用相同的血压范围对正在服用降压药物的个体进行分类。主要结局是一个复合CVD终点,包括心肌梗死、心绞痛、中风和心力衰竭。在平均1050天的随访中,共识别出7039例CVD事件。与正常血压相比,1期高血压(风险比[HR]:1.30,95%置信区间[95%CI]:1.21 - 1.40)和2期高血压(HR:2.17,95%CI:2.01 - 2.34)与未服用药物个体的CVD事件风险增加相关。在服用降压药物的人群中,仅2期高血压范围(HR:1.19,95%CI:1.02 - 1.38)与CVD事件风险增加相关。受限立方样条分析显示,在未服用药物的个体中,收缩压/舒张压(SBP/DBP)>120/80 mmHg时,CVD事件风险随血压单调增加,但在服用降压药物的个体中,仅在SBP/DBP>140/90 mmHg时风险增加。总之,在蛋白尿且eGFR保留的人群中,1期和2期高血压与未服用药物个体的CVD风险增加相关,而在服用降压药物的人群中,仅2期高血压与CVD风险增加相关。